HERTHENA-Lung02
A HER3 ADC delayed progression by only a few days more than chemotherapy and did not extend survival, so its US application was withdrawn.
586 patients. PFS 5.8 vs 5.4 months (HR 0.77, statistically significant but clinically marginal); OS not significant. Daiichi Sankyo and Merck withdrew the accelerated-approval BLA on 29 May 2025. A lesson that ADC activity after TKI does not guarantee benefit over platinum doublets.
- Median 5.8 vs 5.4 months with Patritumab deruxtecan compared with Platinum + pemetrexed; about 0.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 23 percent lower chance of the event at any given time (hazard ratio 0.77, likely range 0.63 to 0.94).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 16.8 vs 16.8 months with Patritumab deruxtecan compared with Platinum + pemetrexed; about 0 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 2 percent lower chance of the event at any given time (hazard ratio 0.98, likely range 0.79 to 1.22).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Not significant.
- These results apply to the people the trial enrolled: EGFR-mutant NSCLC after third-generation TKI: patritumab deruxtecan vs platinum chemotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (EGFR); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
586 participants enrolled.
Not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Patritumab deruxtecan | 293 | 5.8 months | 0.77 (0.63–0.94) | 0.011 | link |
| Platinum + pemetrexed | 293 | 5.4 months | ||||
| Overall survival | Patritumab deruxtecan | — | 16.8 months | 0.98 (0.79–1.22) | — | link |
| Platinum + pemetrexed | — | 16.8 months |
Pages like this
not linked directly; found by shared links- PersonHelena A. Yu
Shares Patritumab deruxtecan, HER3, Non-small-cell lung cancer.
- IdeaBlock the survival signals the tumour's neighbours provide
Shares Patritumab deruxtecan, HER3.
- TrialTROPION-Lung01
Shares Benjamin Besse, Non-small-cell lung cancer.
- PairingEGFR TKI → ADC on progression
- ProductZenocutuzumab
Shares HER3, Non-small-cell lung cancer.
- InstitutionIntergroupe Francophone de Cancérologie Thoracique
Shares Benjamin Besse, Non-small-cell lung cancer.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares HER3, Non-small-cell lung cancer.
- Key paperMARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer
Shares Benjamin Besse, Non-small-cell lung cancer.